MA56224B1 - Composition de stimulation ovarienne contrôlée - Google Patents

Composition de stimulation ovarienne contrôlée

Info

Publication number
MA56224B1
MA56224B1 MA56224A MA56224A MA56224B1 MA 56224 B1 MA56224 B1 MA 56224B1 MA 56224 A MA56224 A MA 56224A MA 56224 A MA56224 A MA 56224A MA 56224 B1 MA56224 B1 MA 56224B1
Authority
MA
Morocco
Prior art keywords
ovarian stimulation
controlled ovarian
stimulation composition
composition
fsh
Prior art date
Application number
MA56224A
Other languages
English (en)
French (fr)
Other versions
MA56224A (fr
Inventor
Lisbeth HELMGAARD
Bjarke Mirner Klein
Joan-Carles ARCE SAEZ
Original Assignee
Ferring B.V.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ferring B.V. filed Critical Ferring B.V.
Publication of MA56224A publication Critical patent/MA56224A/fr
Publication of MA56224B1 publication Critical patent/MA56224B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/24—Follicle-stimulating hormone [FSH]; Chorionic gonadotropins, e.g. HCG; Luteinising hormone [LH]; Thyroid-stimulating hormone [TSH]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/26—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against hormones ; against hormone releasing or inhibiting factors

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Endocrinology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Reproductive Health (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • Pregnancy & Childbirth (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gynecology & Obstetrics (AREA)
  • Biotechnology (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Cell Biology (AREA)
  • General Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MA56224A 2017-09-01 2018-08-31 Composition de stimulation ovarienne contrôlée MA56224B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP17189119 2017-09-01
EP21196378.0A EP3973982B1 (en) 2017-09-01 2018-08-31 Composition for controlled ovarian stimulation

Publications (2)

Publication Number Publication Date
MA56224A MA56224A (fr) 2022-04-20
MA56224B1 true MA56224B1 (fr) 2024-09-30

Family

ID=59772482

Family Applications (2)

Application Number Title Priority Date Filing Date
MA56224A MA56224B1 (fr) 2017-09-01 2018-08-31 Composition de stimulation ovarienne contrôlée
MA50034A MA50034B1 (fr) 2017-09-01 2018-08-31 Composition de stimulation ovarienne contrôlée

Family Applications After (1)

Application Number Title Priority Date Filing Date
MA50034A MA50034B1 (fr) 2017-09-01 2018-08-31 Composition de stimulation ovarienne contrôlée

Country Status (32)

Country Link
US (2) US11744879B2 (enExample)
EP (3) EP4427806A3 (enExample)
JP (2) JP6856819B2 (enExample)
KR (2) KR20200045543A (enExample)
CN (2) CN111050787A (enExample)
AR (1) AR112541A1 (enExample)
AU (1) AU2018326556B2 (enExample)
BR (1) BR112020003379A2 (enExample)
CA (1) CA3073624A1 (enExample)
CL (1) CL2020000482A1 (enExample)
DK (2) DK3973982T3 (enExample)
EA (1) EA202090480A1 (enExample)
ES (2) ES2904787T3 (enExample)
FI (1) FI3973982T3 (enExample)
HR (2) HRP20241171T1 (enExample)
HU (2) HUE056726T2 (enExample)
IL (1) IL272763B2 (enExample)
JO (1) JOP20200034A1 (enExample)
LT (2) LT3973982T (enExample)
MA (2) MA56224B1 (enExample)
MD (2) MD3675894T2 (enExample)
MX (2) MX2020002235A (enExample)
MY (1) MY200791A (enExample)
PH (1) PH12020500404A1 (enExample)
PL (2) PL3675894T3 (enExample)
PT (2) PT3675894T (enExample)
RS (2) RS65945B1 (enExample)
SG (1) SG11202003840QA (enExample)
SI (2) SI3675894T1 (enExample)
TW (1) TWI749255B (enExample)
UA (1) UA126869C2 (enExample)
WO (1) WO2019043143A1 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI846743B (zh) 2018-10-17 2024-07-01 荷蘭商菲林公司 用於控制性卵巢刺激之組成物及方法
TW202237173A (zh) * 2020-12-09 2022-10-01 荷蘭商菲林公司 用於受控的卵巢刺激之組成物及方法

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2217113T5 (es) * 2000-01-27 2008-11-01 Laboratoires Serono Sa Uso de fsh para tratar infertilidad.
US20040248784A1 (en) 2003-06-03 2004-12-09 Marco Filicori Unitary combinations of FSH and hCG
ES2494928T3 (es) * 2007-09-21 2014-09-16 Pharmabrand S.A. Composición que comprende polisacáridos mucilaginosos derivados de Aloe barbadensis combinados con liposomas, procedimiento para la obtención de los mismos y su uso como protector solar, un agente antiacné, un regenerador epidérmico y un hidratante
TWI488640B (zh) 2008-04-16 2015-06-21 Ferring Int Ct Sa 藥學製劑
US20130045933A1 (en) * 2010-01-21 2013-02-21 Ramot At Tel-Aviv University Ltd. Aloe-emodin derivatives and use thereof for the treatment of cancer
RS54214B2 (sr) 2010-09-29 2024-02-29 Ferring Bv Smeša za upotrebu u lečenju infertiliteta
AR090095A1 (es) 2011-06-06 2014-10-22 Ferring Bv Preparacion farmaceutica que comprende hormona estimulante del foliculo recombinante
JO3092B1 (ar) 2011-08-08 2017-03-15 Ferring Bv مركب لتحفيز مسيطر عليه للمبيض
SG11201608132UA (en) * 2014-04-18 2016-11-29 Glycotope Gmbh Controlled ovarian hyperstimulation with improved recombinant human follicle-stimulating hormone
SI3261661T1 (sl) 2015-02-26 2024-03-29 Ferring B.V. Menotropin za zdravljenje neplodnosti
PL3662925T3 (pl) * 2015-04-17 2021-10-25 Ferring B.V. Kompozycja zawierająca FSH do leczenia niepłodności
EA034022B1 (ru) 2015-04-24 2019-12-19 Ферринг Б.В. Способ получения гонадотропина
JP6845813B2 (ja) 2015-06-26 2021-03-24 フェリング ベスローテン フェンノートシャップ 精製および／またはウイルス不活性化の方法
PL3787667T3 (pl) 2018-04-30 2025-07-28 Ferring B.V. Kompozycja do kontrolowanej stymulacji jajników
TWI846743B (zh) 2018-10-17 2024-07-01 荷蘭商菲林公司 用於控制性卵巢刺激之組成物及方法

Also Published As

Publication number Publication date
JP7373479B2 (ja) 2023-11-02
CA3073624A1 (en) 2019-03-07
MX2020002235A (es) 2020-07-20
BR112020003379A2 (pt) 2020-08-25
MY200791A (en) 2024-01-16
HRP20241171T1 (hr) 2024-11-22
DK3675894T3 (da) 2022-01-24
PH12020500404A1 (en) 2021-03-01
ES2904787T3 (es) 2022-04-06
JP6856819B2 (ja) 2021-04-14
CN120617484A (zh) 2025-09-12
MA56224A (fr) 2022-04-20
WO2019043143A1 (en) 2019-03-07
EA202090480A1 (ru) 2020-07-20
DK3973982T3 (da) 2024-09-23
US20200197493A1 (en) 2020-06-25
TW201919687A (zh) 2019-06-01
JP2020528071A (ja) 2020-09-17
IL272763B2 (en) 2024-02-01
KR20250078595A (ko) 2025-06-02
PT3973982T (pt) 2024-09-16
LT3675894T (lt) 2021-12-10
PL3675894T3 (pl) 2022-02-21
MX2024009224A (es) 2024-08-06
AU2018326556A1 (en) 2020-03-05
EP4427806A3 (en) 2024-10-09
ES2989511T3 (es) 2024-11-26
CN111050787A (zh) 2020-04-21
EP3675894A1 (en) 2020-07-08
HRP20211802T1 (hr) 2022-03-04
MA50034A (fr) 2021-05-12
UA126869C2 (uk) 2023-02-15
SI3973982T1 (sl) 2024-10-30
US20240024424A1 (en) 2024-01-25
AR112541A1 (es) 2019-11-06
MD3973982T2 (ro) 2024-11-30
MA50034B1 (fr) 2022-02-28
RS65945B1 (sr) 2024-10-31
PT3675894T (pt) 2022-01-25
MD3675894T2 (ro) 2022-03-31
FI3973982T3 (fi) 2024-09-23
RS62810B1 (sr) 2022-02-28
EP3675894B1 (en) 2021-11-03
US11744879B2 (en) 2023-09-05
EP3973982A1 (en) 2022-03-30
LT3973982T (lt) 2024-09-10
JOP20200034A1 (ar) 2020-02-13
HUE056726T2 (hu) 2022-03-28
TWI749255B (zh) 2021-12-11
AU2018326556B2 (en) 2024-09-26
IL272763B1 (en) 2023-10-01
EP3973982B1 (en) 2024-07-31
KR20200045543A (ko) 2020-05-04
CL2020000482A1 (es) 2020-06-26
HUE068024T2 (hu) 2024-12-28
JP2021046398A (ja) 2021-03-25
IL272763A (en) 2020-04-30
EP4427806A2 (en) 2024-09-11
SI3675894T1 (sl) 2022-01-31
SG11202003840QA (en) 2020-05-28
PL3973982T3 (pl) 2024-11-04

Similar Documents

Publication Publication Date Title
GEAP202415222A (en) Stable formulations of programmed death receptor 1 (pd-1) antibodies and methods of use thereof
NZ793445A (en) Cd73 inhibiting 2,4-dioxopyrimidine compounds
EP4421094A3 (en) Targeted therapeutic agents and uses thereof
MX2017015574A (es) Inhibidores de tirosina quinasa de bruton.
WO2019209962A8 (en) Compounds and uses thereof
PH12019500643A1 (en) Antibodies that bind interleukin-2 and uses thereof
WO2019209948A8 (en) Compounds and uses thereof
MX2019001958A (es) Metodos para tratar la enfermedad de crohn con un anticuerpo anti-nkg2d.
FR3063645B1 (fr) Acefapc pour le traitement des maladies acetylcholine dependantes
PH12021550122A1 (en) Solubilized apyrases, methods and use
MX2018014432A (es) Materiales y metodos relacionados con el diseño del regimen de dosificacion.
MX2025001444A (es) Anticuerpos monoclonales anti-trkb y metodos de uso
MX2019015071A (es) Composiciones y metodos para tratar tauopatias.
PH12020550340A1 (en) Anti-pacap antibody
EA202191058A1 (ru) Антитела против муцина-16 и способы их применения
PH12020551573A1 (en) Pharmaceutical compositions for inhibiting inflammatory cytokines
WO2018033941A3 (en) Pharmaceutical compositions of ibrutinib
MX2020009532A (es) Oligonucleotidos modificados para uso en el tratamiento de tauopatias.
MA42902A (fr) Lymphocytes infiltrant la moelle (mil) en tant que source de lymphocytes t pour une thérapie par des récepteurs chimériques d'un antigène (car)
MA56224B1 (fr) Composition de stimulation ovarienne contrôlée
MX2021015333A (es) Combinaciones de inhibidores para el tratamiento de enfermedades relacionadas con la expresion de dux4.
PH12021550121A1 (en) Methods of treating hfpef employing dapagliflozin and compositions comprising the same
MX388998B (es) Uso de mir101 o mir128 en el tratamiento de trastornos convulsivos.
MY199547A (en) Phosphaplatin liquid formulations
MA53909B1 (fr) Compositions et méthodes de stimulation ovarienne contrôlée